{
  "guideline": {
    "id": "PA166222801",
    "name": "Annotation of DPWG Guideline for flucytosine and DPYD",
    "source": "DPWG",
    "version": 10,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166222801",
    "relatedChemicals": [
      {
        "id": "PA449654",
        "name": "flucytosine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA145",
        "name": "dihydropyrimidine dehydrogenase",
        "symbol": "DPYD"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166299164",
      "name": "Recommendation PA166299164",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449654",
          "name": "flucytosine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061527,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": [
        "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to react to fluorouracil, but generally tolerate low doses (approximately 50% of the standard fluorouracil dose)."
      ],
      "lookupKey": {
        "DPYD": "1.0 (Intermediate Metabolizer)"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166301782",
      "name": "Recommendation Annotation PA166301782",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA449654",
          "name": "flucytosine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452102461,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea.\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": [
        "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (15-50% of the standard fluorouracil dose)."
      ],
      "lookupKey": {
        "DPYD": "1.0 (Phenotyping)"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299163",
      "name": "Recommendation PA166299163",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449654",
          "name": "flucytosine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061526,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": [
        "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (50-75% of the standard fluorouracil dose)."
      ],
      "lookupKey": {
        "DPYD": "1.5 (Intermediate Metabolizer)"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166299162",
      "name": "Recommendation PA166299162",
      "population": null,
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449654",
          "name": "flucytosine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061525,
        "html": "<p>The guideline does not provide a recommendation for flucytosine in patients with a DPYD activity score of 2.</p>\n"
      },
      "implications": [
        "The guideline does not provide a description of the impact of a DPYD activity score of 2 on flucytosine."
      ],
      "lookupKey": {
        "DPYD": "2.0 (Normal Metabolizer)"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299160",
      "name": "Recommendation PA166299160",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449654",
          "name": "flucytosine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061523,
        "html": "<p>Avoid flucytosine</p>\n"
      },
      "implications": [
        "A risk of life-threatening toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil and patients with this gene variation are intolerant even to small quantities of fluorouracil."
      ],
      "lookupKey": {
        "DPYD": "0.0 (Poor Metabolizer)"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": true,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166299161",
      "name": "Recommendation PA166299161",
      "population": null,
      "classification": {
        "term": "N/A",
        "termId": "guidelineStrength:981501929"
      },
      "relatedChemicals": [
        {
          "id": "PA449654",
          "name": "flucytosine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452061524,
        "html": "<ul>\n<li>Be alert to the occurrence of severe side effects, such as leukopaenia, neutropaenia, thrombocytopaenia and diarrhoea.\n<ul>\n<li>In the majority of cases, side effects of flucytosine occur in the first two to three weeks of the treatment. Flucytosine should be stopped if severe side effects occur.</li>\n</ul>\n</li>\n</ul>\n"
      },
      "implications": [
        "A very low risk of severe toxicity is increased by gene variation. A small proportion of flucytosine is converted to fluorouracil. Patients with this gene variation are more likely to have a reaction to fluorouracil, but generally tolerate low doses (15-50% of the standard fluorouracil dose)."
      ],
      "lookupKey": {
        "DPYD": "0.5 (Phenotyping)"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [],
  "version": "2023-12-19-10-38"
}